L7 Informatics

The company's primary offering is the L7|ESP (Enterprise Science Platform), a unified and regulatory-compliant platform designed to streamline and automate workflows. L7 Informatics targets a broad client base, including therapeutics, diagnostics, research, and agrochemical industries, ranging from early-stage biotechs to global contract development and manufacturing organizations (CDMOs). The business model is centered on providing this comprehensive software-as-a-service (SaaS) platform that integrates disparate systems like LIMS, ELN, and MES into a single operational framework. This approach aims to reduce operational overhead and simplify IT ecosystems for its clients.

L7|ESP functions by connecting and orchestrating laboratory and manufacturing processes, which breaks down data silos and ensures data is structured and ready for AI applications at its source. The platform includes a suite of built-in applications for functions such as sample management, inventory, electronic batch records, and environmental monitoring. A key feature is its low-code/no-code toolkit, L7|MASTER, which allows users to build their own data models and workflows. The platform is designed to be compliant with GLP, GCP, and GMP standards, providing a full audit trail for enhanced regulatory compliance. By harmonizing data and processes, L7|ESP facilitates more efficient technology transfers and supports operational excellence across the value chain.

Financially, the company is privately held and backed by venture capital. It has successfully raised a total of $55-59.2 million over several funding rounds, with its Series C round in June 2022 raising $38 million, led by Banneker Partners. This capital is intended to accelerate the commercialization of the L7|ESP platform and expand its product portfolio to meet the growing demand in the life sciences market.